| Literature DB >> 34315806 |
Ivan K Chinn1, Zhihui Xie2, Eunice C Chan2, Bianca M Nagata3, Alexey Koval4,5, Wei-Sheng Chen2, Fan Zhang6, Sundar Ganesan7, Diana N Hong1, Motoshi Suzuki8, Glenn Nardone8, Ian N Moore3, Vladimir L Katanaev4,5, Andrea E Balazs1, Chengyu Liu6, James R Lupski9,10, Jordan S Orange11, Kirk M Druey12.
Abstract
We report the clinical and molecular phenotype of three siblings from one family, who presented with short stature and immunodeficiency and carried uncharacterized variants in RGS10 (c.489_491del:p.E163del and c.G511T:p.A171S). This gene encodes regulator of G protein signaling 10 (RGS10), a member of a large family of GTPase-activating proteins (GAPs) that targets heterotrimeric G proteins to constrain the activity of G protein-coupled receptors, including receptors for chemoattractants. The affected individuals exhibited systemic abnormalities directly related to the RGS10 mutations, including recurrent infections, hypergammaglobulinemia, profoundly reduced lymphocyte chemotaxis, abnormal lymph node architecture, and short stature due to growth hormone deficiency. Although the GAP activity of each RGS10 variant was intact, each protein exhibited aberrant patterns of PKA-mediated phosphorylation and increased cytosolic and cell membrane localization and activity compared to the wild-type protein. We propose that the RGS10 p.E163del and p.A171S mutations lead to mislocalization of the RGS10 protein in the cytosol, thereby resulting in attenuated chemokine signaling. This study suggests that RGS10 is critical for both immune competence and normal hormonal metabolism in humans and that rare RGS10 variants may contribute to distinct systemic genetic disorders.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34315806 PMCID: PMC8522579 DOI: 10.1126/scisignal.abc1940
Source DB: PubMed Journal: Sci Signal ISSN: 1945-0877 Impact factor: 9.517